Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002833 · ClinicalTrials.gov registry record · Phase 2
Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
NCT00002833: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00002833 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 53 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002833, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Colony stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation plus filgrastim in treating patients who have acute or chronic myelogenous leukemia.
Interventions
- DRUG Cladribine
- BIOLOGICAL Filgrastim
- DRUG Fludarabine Phosphate
- DRUG Cyclosporine
- DRUG Cytarabine (Ara-C)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 1994-10 |
| Est. Completion | 2002-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002833
The ClinicalTrials.gov registry entry for NCT00002833 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cladribine is the first listed.
NCT00002833 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002833 about?
NCT00002833 is a clinical study titled "Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Colony stimulating fac...
What is the current status of trial NCT00002833?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 1994-10. Estimated completion is 2002-04.
What interventions are being tested in trial NCT00002833?
The interventions under investigation include: Cladribine (DRUG), Filgrastim (BIOLOGICAL), Fludarabine Phosphate (DRUG), Cyclosporine (DRUG), Cytarabine (Ara-C) (DRUG).
Who is sponsoring clinical trial NCT00002833?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.